A number of studies have shown modest increases in clinical activity such as the study by Schwartzentruber et al. in 2011 that showed that patients with advanced melanoma treated with IL-2 and a gp100 peptide vaccine fared better than patients treated with IL-2 alone (median OS 18 versus 11 months, respectively) (48, 235). Here, IL2 is linked to melanoma.